Enanta Pharmaceuticals
ENTA
109 hedge funds and large institutions have $103M invested in Enanta Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 38 reducing their positions, and 17 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
2% more funds holding
Funds holding: 107 → 109 (+2)
3% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 38
6.63% less ownership
Funds ownership: 93.95% → 87.32% (-6.6%)
10% less capital invested
Capital invested by funds: $114M → $103M (-$11.7M)
56% less call options, than puts
Call options by funds: $35K | Put options by funds: $79K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.78M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.92M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.6M |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$952K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$464K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.97M |
| 2 |
Morgan Stanley
New York
|
-$4.55M |
| 3 |
CP
Caligan Partners
New York
|
-$1.06M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$577K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$495K |
ENTA Hedge Fund Activity: Q1 2025 in Review
109 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2025, worth a combined $103M — down 10% from $114M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ENTA positions and 17 closed out — a net gain of 2 holders — while 37 added to existing stakes and 38 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.78M. The largest seller was RA Capital Management, exiting entirely with an estimated $5.97M sold.
- 109 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2025, up from 107 in Q4 2024.
- Funds reported $103M of Enanta Pharmaceuticals stock for Q1 2025, down 10% quarter-over-quarter.
- 19 funds opened new Enanta Pharmaceuticals positions in Q1 2025 and 17 closed out, a net change of +2 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2025 was Millennium Management, an estimated $2.78M added.
- The largest Enanta Pharmaceuticals seller in Q1 2025 was RA Capital Management, an estimated $5.97M sold.
Based on aggregated 13F filings for Q1 2025.